Showing results (51-60 of 78) with videos related to
Sort By:
Pageof 8
Research in Developmental Disabilities|March 27, 2019
Can I teach students with Autism Spectrum Disorder?: Investigating teacher self-efficacy with an emerging population of studentsAbigail M A Love, Michael D Toland, Ellen L Usher, et al.Infection and Immunity|June 1, 1997
Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteersD A Sack, J Shimko, R B Sack, et al.Drug and Chemical Toxicology|August 1, 1997
Pharmacokinetics and pharmacodynamics of 4-aminopyridine in awake guinea pigsB R Capacio, F C Chang, D Spriggs, et al.Investigational New Drugs|January 1, 1994
Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancerD L Trump, J A Hathorn, L B Grochow, et al.Gynecologic Oncology|November 5, 1997
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-upF Shapiro, J Schneider, M Markman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancerD Fennelly, C Aghajanian, F Shapiro, et al.Journal of Autism and Developmental Disorders|July 19, 2020
Measuring Police Officer Self-efficacy for Working with Individuals with Autism Spectrum DisorderAbigail M A Love, Ellen L Usher, Michael D Toland, et al.Gynecologic Oncology|May 8, 1998
A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessmentR R Barakat, L Almadrones, E S Venkatraman, et al.Gynecologic Oncology|March 30, 1999
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancerA Husain, P Sabbatini, D Spriggs, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 7, 2006
Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?J Dupont, C Aghajanian, G Andrea, et al.Pageof 8